Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.

Marianne B. Treppendahl, MD, Magnus Tobiasson, MD, Anni Aggerholm, PhD, Mohsen Karimi, PhD, Trine Silkjaer, MD, Lone S. Friis, MD, PhD, Mette K. Andersen, PhD, Lars Kjeldsen, MD, PhD, Mette S. Holm, MD, PhD, Eva Hellström-Lindberg, PhD, Kirsten Grønbæk, MD, DMSc

Blood (2012) 120 (21): 2394.

https://doi.org/10.1182/blood.V120.21.2394.2394

Published: 2012

Journal Articles

Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,

Magnus Tobiasson, MD, Lena Brandefors, MD, Ingunn Dybedal, MD, PhD, Hege Garelius, MD, Michael Grövdal, MD, PhD, Inge Hoegh Dufva, MD, PhD, Lars Kjeldsen, MD, PhD, Lars Nilsson, MD, PhD, Astrid Olsnes Kittang, MD, PhD, Anna Porwit, MD, PhD, Leonie Saft, MD, Mette Skov Holm, MD, PhD, Lars Möllgård, MD, Phd, Eva Hellström-Lindberg

Blood (2011) 118 (21): 3798.

https://doi.org/10.1182/blood.V118.21.3798.3798

Published: 2011

Journal Articles

Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry

Louise de Swart, Alex Smith, Pierre Fenaux, MD, PhD, David Bowen, Guillermo Sanz, MD, Eva Hellström-Lindberg, Argyris Symeonidis, Jaroslav Cermak, MD, PhD, Ulrich Germing, MD, Reinhard Stauder, MD, Otilia Georgescu, Marius MacKenzie, Luca Malcovati, MD, Mette Skov Holm, MD, PhD, Sophie Park, Odile Beyne-Rauzy, Jackie Droste, Theo de Witte, MD, PhD

Blood (2011) 118 (21): 2775.

https://doi.org/10.1182/blood.V118.21.2775.2775

Published: 2011

Journal Articles

Somatic Mutation of SF3B1 , a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts

Blood (2011) 118 (21): 3.

https://doi.org/10.1182/blood.V118.21.3.3

Published: 2011

Journal Articles

Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged < 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis

Pierre Fenaux, MD, PhD, Aristoteles Giagounidis, MD, Alan F. List, MD, Stephen D. Nimer, MD, Eva Hellström-Lindberg, Bayard L. Powell, MD, Xujie Yu, PhD, Barry Skikne, MD, Jamile M. Shammo, MD, Consuelo del Cañizo, MD

Blood (2011) 118 (21): 1723.

https://doi.org/10.1182/blood.V118.21.1723.1723

Published: 2011

Journal Articles

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells

Andrea Pellagatti, Mario Cazzola, Aristoteles Giagounidis, Janet Perry, Luca Malcovati, Matteo G. Della Porta, Martin Jädersten, Sally Killick, Paresh Vyas, Eva Hellström-Lindberg, Jacqueline Boultwood, James S. Wainscoat

Blood (2010) 116 (21): 298.

https://doi.org/10.1182/blood.V116.21.298.298

Published: 2010

Journal Articles

Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry

Louise de Swart, Alex Smith, Pierre Fenaux, Argyris Symeonidis, Eva Hellström-Lindberg, Guillermo Sanz, Jaroslav Cermak, Otilia Georgescu, Ulrich Germing, Marius MacKenzie, Odile Beyne-Rauzy, Luca Malcovati, Reinhard Stauder, Jackie Droste, David Bowen, Theo de Witte

Blood (2010) 116 (21): 2917.

https://doi.org/10.1182/blood.V116.21.2917.2917

Published: 2010

Journal Articles

Short Telomeres Before Lenalidomide Treatment Predict Leukemic Progression In Patients with Myelodysplastic Syndrome and Deletion 5q

Gudrun Göhring, Kathrin Lange, Winfried Hofmann, Kirsten Vang Nielsen, Eva Hellström-Lindberg, Lydia Roy, MD, Michael Morgan, Hans Kreipe, Guntram Büsche, Aristoteles Giagounidis, Brigitte Schlegelberger

Blood (2010) 116 (21): 30.

https://doi.org/10.1182/blood.V116.21.30.30

Published: 2010

Journal Articles

Mutation Analysis of TET2 Reveals the Clonal Nature of Refractory Anemia with Ring Sideroblasts

Luca Malcovati, Angela Brisci, Anna Gallì, Francesca Bruno, Erica Travaglino, Andrea Pellagatti, Matteo G Della Porta, Maurizio Ferrari, Jacqueline Boultwood, Laura Cremonesi, Eva Hellström-Lindberg, Mario Cazzola

Blood (2010) 116 (21): 1862.

https://doi.org/10.1182/blood.V116.21.1862.1862

Published: 2010

Journal Articles

Transcriptome Analysis of Differentiating Erythroid Progenitors in Refractory Anemia with Ringed Sideroblasts

Per Unneberg, Maryam Nikpour, Liselotte Vesterlund, Monika Jansson, Juha Kere, Eva Hellström-Lindberg

Blood (2010) 116 (21): 1864.

https://doi.org/10.1182/blood.V116.21.1864.1864

Published: 2010

Journal Articles

Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004)

Pierre Fenaux, MD, PhD, Aristotles Giagounidis, MD, Odile Beyne-Rauzy, MD, PhD, Ghulam Mufti, MD, DM, FRCP, FRCPath, Moshe Mittelman, MD, Petra Muus, MD, PhD, Peter te Boekhorst, MD, PhD, Guillermo Sanz, MD, PhD, Mario Cazzola, MD, Jay Backstrom, MD, Tommy Fu, PhD, Eva Hellström-Lindberg, MD, PhD

Blood (2010) 116 (21): 4027.

https://doi.org/10.1182/blood.V116.21.4027.4027

Published: 2010

Journal Articles

Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities.

Lars Möllgård, Lars Nilsson, Lars Kjeldsen, Ingunn Dybedal, Inge Hogh Dufva, Hege Garelius, Jan Maxwell Norgaard, Olle Linder, Elisabeth Ejerblad, Jan Astermark, Eva Hellström-Lindberg

Blood (2009) 114 (22): 115.

https://doi.org/10.1182/blood.V114.22.115.115

Published: 2009

Journal Articles

Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia.

Jacqueline Boultwood, Janet Perry, Andrea Pellagatti, Aristoteles Giagounidis, Luca Malcovati, Matteo G Della Porta, Martin Jädersten, Sally Killick, Eva Hellström-Lindberg, Mario Cazzola, James S Wainscoat

Blood (2009) 114 (22): 419.

https://doi.org/10.1182/blood.V114.22.419.419

Published: 2009

Journal Articles

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells.

Andrea Pellagatti, Mario Cazzola, Aristoteles Giagounidis, Janet Perry, Luca Malcovati, Matteo G Della Porta, Martin Jädersten, Sally Killick, Amit Verma, MD, Eva Hellström-Lindberg, James S Wainscoat, Jacqueline Boultwood

Blood (2009) 114 (22): 735.

https://doi.org/10.1182/blood.V114.22.735.735

Published: 2009

Journal Articles

Different Incidence and Implications of DNA Hypermethylation in De Novo AML Compared to High-Risk MDS and AML Following MDS.

Stefan Deneberg, Michael Grövdal, Monika Jansson, Verena I. Gaidzik, Andrea Corbacioglu, Hareth Nahi, MD, PhD, Sofia Bengtzen, Konstanze Döhner, Christer Paul, Eva Hellström-Lindberg, Sören Lehmann, MD, PhD

Blood (2008) 112 (11): 3337.

https://doi.org/10.1182/blood.V112.11.3337.3337

Published: 2008

Journal Articles

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr–ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

Michael Grövdal, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Jan Astermark, Per Bernell, Lena-Maria Engström, Lars Kjeldsen, Olle Linder, Lars Nilsson, Anna Olsson, Jonas Wallvik, Jon Magnus Tangen, Gunnar Öberg, Sten Eirik Jacobsen, Anna Porwit, Peter Hokland, Eva Hellström-Lindberg

Blood (2008) 112 (11): 223.

https://doi.org/10.1182/blood.V112.11.223.223

Published: 2008

Journal Articles

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

John F Seymour, MBBS, PhD, FRACP, Pierre Fenaux, MD, PhD, Lewis B. Silverman, MD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Valeria Santini, MD, Alan F. List, MD, Steven D. Gore, MD, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L. Beach, PharmD

Blood (2008) 112 (11): 3629.

https://doi.org/10.1182/blood.V112.11.3629.3629

Published: 2008

Journal Articles

Clonal Heterogeneity in the 5q- Syndrome: NPMc+ and p53 Expressing Progenitors Are Insensitive to Lenalidomide Treatment and Expand at Disease Progression

Martin Jädersten, Leonie Saft, Andrea Pellagatti, Gudrun Göhring, Cristina Fernández-Santamaria, James S Wainscoat, Jacqueline Boultwood, Anna Porwit, Brigitte Schlegelberger, Eva Hellström-Lindberg, MD, PhD

Blood (2008) 112 (11): 5104.

https://doi.org/10.1182/blood.V112.11.5104.5104

Published: 2008

Journal Articles

Long-Term Cytogenetic Follow-up of MDS Patients with 5q- Treated within the MDS-003 (CC-5013-MDS-003) Study: Evolution to Complex Clones and Progression to AML.

Gudrun Göhring, MD, Aristoteles Giagounidis, Carlo Aul, Guntram Büsche, MD, Hans Kreipe, MD, Eva Hellström-Lindberg, MD, PhD, Robert D. Knight, MD, Brigitte Schlegelberger, MD

Blood (2008) 112 (11): 1647.

https://doi.org/10.1182/blood.V112.11.1647.1647

Published: 2008

Journal Articles

Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).

Valeria Santini, MD, Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Lewis B. Silverman, MD, Alan List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L Beach, PharmD

Blood (2008) 112 (11): 1653.

https://doi.org/10.1182/blood.V112.11.1653.1653

Published: 2008

NARROW

Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.

Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,

Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry

Somatic Mutation of SF3B1 , a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts

Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged < 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells

Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry

Short Telomeres Before Lenalidomide Treatment Predict Leukemic Progression In Patients with Myelodysplastic Syndrome and Deletion 5q

Mutation Analysis of TET2 Reveals the Clonal Nature of Refractory Anemia with Ring Sideroblasts

Transcriptome Analysis of Differentiating Erythroid Progenitors in Refractory Anemia with Ringed Sideroblasts

Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004)

Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities.

Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia.

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells.

Different Incidence and Implications of DNA Hypermethylation in De Novo AML Compared to High-Risk MDS and AML Following MDS.

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr–ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

Clonal Heterogeneity in the 5q- Syndrome: NPMc+ and p53 Expressing Progenitors Are Insensitive to Lenalidomide Treatment and Expand at Disease Progression

Long-Term Cytogenetic Follow-up of MDS Patients with 5q- Treated within the MDS-003 (CC-5013-MDS-003) Study: Evolution to Complex Clones and Progression to AML.

Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only